LGF
TEVA icon

LGT Group Foundation’s Teva Pharmaceuticals TEVA Stock Holding History

LGT Group Foundation’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-101,000
Closed -$815K – 272
2022
Q3 		$815K Hold
101,000
– – 0.03% 203
2022
Q2 		$760K Hold
101,000
– – 0.02% 210
2022
Q1 		$948K Hold
101,000
– – 0.02% 218
2021
Q4 		$809K Buy
+101,000
New +$912K 0.02% 213

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

LGT Group Foundation's TEVA Position: Q4 2022 in Review

LGT Group Foundation sold out of Teva Pharmaceuticals (TEVA) in Q4 2022, closing a stake of 101,000 shares — an estimated $815K sold.

LGT Group Foundation first reported a position in TEVA in Q4 2021 and held it in 4 quarters. The position peaked at $948K in Q1 2022. 422 funds tracked by Wall St. Rank hold TEVA as of Q4 2022.

  • LGT Group Foundation reported no remaining Teva Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • LGT Group Foundation sold 101,000 Teva Pharmaceuticals shares in Q4 2022, an estimated $815K.
  • LGT Group Foundation first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • LGT Group Foundation's Teva Pharmaceuticals position peaked at $948K in Q1 2022.
  • 422 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2022.

Based on LGT Group Foundation's 13F filing for Q4 2022, filed 9 Feb 2023.